Syndax Pharmaceuticals Inc (SNDX) - Total Liabilities
Based on the latest financial reports, Syndax Pharmaceuticals Inc (SNDX) has total liabilities worth $431.05 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Syndax Pharmaceuticals Inc - Total Liabilities Trend (2011–2025)
This chart illustrates how Syndax Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See how liquid is Syndax Pharmaceuticals Inc's working capital to evaluate short-term liquidity relative to the company's equity base.
Syndax Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Syndax Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Baldwin Insurance Group, Inc.
NASDAQ:BWIN
|
USA | $4.39 Billion |
|
UIE PLC
CO:UIE
|
Denmark | Dkr121.46 Million |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥1.64 Billion |
|
Bank Ocbc Nisp Tbk
JK:NISP
|
Indonesia | Rp254.89 Trillion |
|
Australian United Investment Company Ltd
AU:AUI
|
Australia | AU$399.22 Million |
|
Makalot Industrial Co Ltd
TW:1477
|
Taiwan | NT$11.36 Billion |
|
Banpu Public Company Limited
BK:BANPU
|
Thailand | ฿9.39 Billion |
|
Fufeng Group Limited
F:FFO1
|
Germany | €24.25 Billion |
Liability Composition Analysis (2011–2025)
This chart breaks down Syndax Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Syndax Pharmaceuticals Inc worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.47 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 10.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.91 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Syndax Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Syndax Pharmaceuticals Inc (2011–2025)
The table below shows the annual total liabilities of Syndax Pharmaceuticals Inc from 2011 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $465.08 Million | +6.50% |
| 2024-12-31 | $436.69 Million | +644.14% |
| 2023-12-31 | $58.68 Million | +97.01% |
| 2022-12-31 | $29.79 Million | -27.86% |
| 2021-12-31 | $41.29 Million | -14.74% |
| 2020-12-31 | $48.42 Million | +51.68% |
| 2019-12-31 | $31.93 Million | +3.35% |
| 2018-12-31 | $30.89 Million | -6.01% |
| 2017-12-31 | $32.87 Million | +32.13% |
| 2016-12-31 | $24.87 Million | +7.19% |
| 2015-12-31 | $23.20 Million | +25.22% |
| 2014-12-31 | $18.53 Million | +255.56% |
| 2013-12-31 | $5.21 Million | -83.08% |
| 2012-12-31 | $30.80 Million | +29.18% |
| 2011-12-31 | $23.84 Million | -- |
About Syndax Pharmaceuticals Inc
Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. Th… Read more